Effects of fixed-dose indapamide/perindopril combination on arterial function in patients with hypertension and chronic kidney disease: key results of the CAMERTON program

Aim. To study the effects of fixed-dose indapamide/perindopril combination on endothelial function and arterial stiffness in patients with uncontrolled stage 1-2 hypertension (HTN) and chronic kidney disease (CKD).

Material and methods. Total of 100 patients with uncured or uncontrolled with ≥3 months antihypertensive therapy HTN and CKD G3 (67% females, mean age 59,1±12,5 years) were included in the study. Each patient took indapamide/perindop combination in accordance with 1 of 3 existing regimes (depending on doses) for 3 months. Primary aim was to assess the effects of indapamide/perindopril combination on endothelial function and parameters of arterial stiffness after 12 weeks of treatment (assessment by AngioScan diagnostic complex). Secondary aims were achievement of target blood pressure (BP) after 4 and 12 weeks of therapy and assessment of glomerular filtration rate (GFR) and the albumin-tocreatinine ratio (ACR) changes after 12 weeks.

Results. Initially, there was an increase in arterial stiffness parameters in all patients, and during treatment decrease was observed: central systolic BP (SBP) from 120±10,1 to 112,9±6,3 mm Hg, median augmentation index from 10,9% to 4,6%, stiffness index from 8,1±2,4 to 7,1±0,9, vascular age decreased by 9,6% (р< 0,001 for trend). Significant improvement of endothelial function was observed regardless of diabetes presence: occlusion index increased from 1,5±0,3 to 1,7±0,5, median phase shift — from -4,6 to -2,4 ms (p< 0,01). After 4 weeks, 27% of patients reached target BP, by the end of the study — 90%. A decrease in the median ACR from 16,3 to 15,0 mg/g, GFR increase from 50,2±7,6 to 53,6±8,7 ml/min/1,73 m² were observed (p< 0,01 for trend).

Conclusion. Therapy with a fixed-dose indapamide/perindopril combination in patients with uncontrolled stage 1-2 HTN and G3 CKD leads to a significant improvement in arterial stiffness, endothelial and renal function, and achievement of target BP in 90% of patients.

1. Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One 2016;11(7):e0158765. doi: 10.1371/journal.pone.0158765.

2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 36(10):1953-2041. doi: 10.1097/HJH.0000000000001940.

3. Niiranen TJ, Kalesan B, Hamburg NM, et al. Relative Contributions of Arterial Stiffness and Hypertension to Cardiovascular Disease: The Framingham Heart Study. J Am Heart Assoc. 2016; 5(11). doi: 10.1161/JAHA.116.004271.

4. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012; 221(1):18-33. doi: 10.1016/j.atherosclerosis.2011.12.005.

5. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006; 113(9):1213-25. doi: 10.1161/CIRCULATIONAHA.105.595496.

6. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007; 73(1):237-46. doi: 10.1016/j.cardiores.2006.10.021.

7. Yugar LBT, Moreno B, Moreno H. Do thiazide diuretics reduce central systolic blood pressure in hypertension? J Clin Hypertens (Greenwich). 2018; 20(1):133-135. doi: 10.1111/jch.13134.

8. Borisova EV, Kochetkov AI, Ostroumova OD. Single Pill Indapamide and Perindopril Arginine Combination: Optimal Coupling of Vascular Protection and Hemodynamic Risk Factors Reduction in Patients with Essential Arterial Hypertension. Kardiologiia. 2019;59(3):18-26. (In Russ). doi: 10.18087/cardio.2019.3.10236.

9. Mourad JJ, Lameira D, Guillausseau PJ. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag. 2008;4(2):443-51. doi: 10.2147/vhrm.s2778.

10. Patel A, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590):829-40. doi: 10.1016/S0140-6736(07)61303-8.

11. Smirnov AV, Shilov EM, Dobronravov VA, et al. National guidelines. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Nephrology 2012;16(1):89-115 (In Russ.)

12. Angioscan-01. Diagnostic complex for the analysis of the cardiovascular system. User manual. 2015 LLC “Angioscan electronics”. (In Russ.)

13. Asmar RG, London GM, O'Rourke ME, et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001; (4):922-6. doi: 10.1161/hy1001.095774.

14. Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension. 2003; (5):1063-71. doi: 10.1161/01.HYP.0000064943.51878.58.

15. Vikulova O.K., Yarek-Martinova I.R., Trubitsina N.P. Endothelial function and arterial wall elasticity in patients with type 2 diabetes mellitus receiving ramipril. Kardiologiia 2008;11:47-52 (In Russ).

16. Instruction for medical use of the drug Noliprel A Bi-Forte. Registration certificate LSR-008847 from 30.08.2010. (In Russ.)